Carlos Pãrez-Medina

Icahn School Of Medicine At Mount Sinai

$1,324,529

Attributed

$3,618,800

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $758.8K · FY2018–22

$1M$750K$500K$250K$0

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$3,618,800 · 1

By mechanism

R01$3,618,800 · 1

Top collaborators

Zahi A. Fayad3 shared
Thomas Reiner3 shared
Willem Mulder2 shared
Jan Grimm1 shared

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Willem Mulder$11,953,843
Darrell J Irvine$37,519,809
Michael Schotsaert$3,271,645
Juan P Wisnivesky$34,328,417
Chung Yin Kong$10,200,842

Others in their field

Other Emerging Leaders on “Anti-Cancer”

Leonard Freedman · Leidos Biomedical Research, Inc.$246,654,132
Lynn Briscoe · Leidos Biomedical Research, Inc.$131,271,272
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$58,795,816
Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Douglas S. Hawkins · Children'S Hosp Of Philadelphia$50,338,647
Dwayne Forquer · Leidos Biomedical Research, Inc.$21,434,446

Research focus

Anti-CancerAnti-Cancer TherapeuticAwardBaseBiological MarkersBreast Cancer ModelBreast Cancer TherapyBt 474Cancer ModelCancerousCellsChemotherapyClinically RelevantClinical TranslationCollaborationsCompanionsComplementControlled ReleaseDaunorubicinDeveloped CountriesDosageDoxorubicinDoxorubicin Hydrochloride LiposomeAffect